 |
|
Program Overview
|
|
Because of the protracted and unpredictable clinical course of MS, biological surrogate markers are much needed to make the assessment of disease-modifying treatments more efficient. MRI outcome measures (gadolinium enhancement; T1/T2 abnormalities; progressive, diffuse axonal loss) are now widely used to monitor treatment outcome in MS and may be considered as surrogate markers for clinical relapses. This CME will provide an opportunity for neurologists to understand the use of surrogate markers in the monitoring of disease-modifying therapy.
|
|
|
Target Audience
|
|
This activity has been designed to meet the educational needs of neurologists involved in the management of patients with multiple sclerosis
|
|
|
Goal Statement
|
|
This CME will provide an opportunity for neurologists to understand the use of surrogate markers in the monitoring of disease-modifying therapy.
|
|
|
Learning Objectives
|
|
At the conclusion of this activity, participants should be able to:
- Describe the various surrogate markers that may be used to monitor disease-modifying therapy in MS.
- Explain the pathophysiology underlying the progression to disability in MS.
- Review the correlation between surrogate markers and progression to disability.
- Explain how a reduction in relapse rates may not always be related to a reduction in disability.
- Describe treatment options that have been shown to delay the progression of disability.
|
|
|
Faculty:
|
|
J. Theodore Phillips, Jr., MD, PhD (Moderator)
Multiple Sclerosis Center at Texas Neurology, Baylor University Medical Center
Dr. Ted Phillips is a graduate of the University of Texas at Austin with special honors in chemistry, and received MD and PhD (Immunology) degrees and Neurology Residency training from the University of Texas Southwestern Medical Center at Dallas. He is director of the Multiple Sclerosis Center at Texas Neurology in Dallas, and serves as a Clinical Associate Professor of Neurology at the University of Texas Southwestern Medical Center and Attending Neurologist at Baylor University Medical Center in Dallas. He is a principal developer of a national registry for MS (MSTRAC) and is a principal investigator in several ongoing clinical treatment trials in MS.
Mariko Kita, MD
Virginia Mason Medical Center, Seattle
Dr. Kita attended medical school at the Northwestern University School of Medicine, residency in neurology at the Hospital of the University of Pennslyvania, internship in internal medicine at Northwestern Memorial Hospital and a fellowship in neuroimmunology at Mt. Zion Multiple Sclerosis Center, University of California School of Medicine.
Dr. Kita is currently Director of the Virginia Mason Multiple Sclerosis Center and is board certified by the American Board of Psychiatry and Neurology.
Norman J. Kachuck, MD
University of Southern California School of Medicine
Norman J. Kachuck, MD, is an associate professor of clinical neurology, co-director of the neuroimmunology service of the department of neurology and director of the USC Multiple Sclerosis Research Group. He earned his MD and completed his training at USC. He also holds a BA in musical composition and performance from UC San Diego.
Dr. Kachuck's clinical interests include multiple sclerosis, immunomodulation and the nervous system. He is the director of the MS Comprehensive Care Center at USC University Hospital and is involved in clinical trials with new MS medications. |
|
|
Instructions for CME Credit
|
|
Physician Continuing Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine and Healthology. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Faculty Disclosure Statements
The Postgraduate Institute for Medicine has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.
|
|
|
Faculty Disclosure Statement
|
|
J. Theodore Phillips, Jr., MD, PhD
Speakers’ Bureau: Biogen Idec
Mariko Kita, MD
Grants/Research Support: Biogen Idec
Norman J. Kachuck, MD
Nothing to Disclose
|
|
|
Method of Participation
|
|
There are no fees for participating and receiving CME credit for this activity. During the period July 2005 through July 2006, participants must: 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the Evaluation Form; 4) complete the Evaluation Form; and 5) mail or fax the Evaluation Form with answer key to the Postgraduate Institute for Medicine.
A statement of credit will be issued only upon receipt of a completed activity Evaluation Form and a completed post-test with a score of 70 percent or better. Your statement of credit will be mailed to you within three weeks.
|
|
|
Media
|
|
Internet
|
|
|
Disclosure of Unlabeled Use
|
|
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The Postgraduate Institute for Medicine (PIM), Healthology and Biogen Idec do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Healthology and Biogen Idec. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
|
|
|
Disclaimer
|
|
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Produced by Healthology © 2005
|
|
|
Launch Presentation
|
|
Launch Multimedia Format
Launch Text Format
|
|
